{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T18:51:59Z","timestamp":1788375119218,"version":"build-2803163510"},"reference-count":82,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2018ZX10711001-006"],"award-info":[{"award-number":["2018ZX10711001-006"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biosafety and Biosecurity"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jobb.2022.12.004","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T23:17:23Z","timestamp":1672874243000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Potential threat of human pathogenic orthopoxviruses to public health and control strategies"],"prefix":"10.1016","volume":"5","author":[{"given":"Yongli","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongjuan","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jobb.2022.12.004_b0005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.vetmic.2011.04.010","article-title":"Zoonotic cases of camelpox infection in India","volume":"152","author":"Bera","year":"2011","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.jobb.2022.12.004_b0010","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.coviro.2011.11.007","article-title":"Poxvirus host cell entry","volume":"2","author":"Schmidt","year":"2012","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.jobb.2022.12.004_b0015","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.tim.2008.07.009","article-title":"Vaccinia virus morphogenesis and dissemination","volume":"16","author":"Roberts","year":"2008","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.jobb.2022.12.004_b0020","article-title":"Viral loads in clinical samples of men with monkeypox virus infection: a French case series","author":"Palich","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jobb.2022.12.004_b0025","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jinf.2022.05.028","article-title":"Transmission of monkeypox virus through sexual contact - A novel route of infection","volume":"85","author":"Heskin","year":"2022","journal-title":"J Infect"},{"key":"10.1016\/j.jobb.2022.12.004_b0030","series-title":"Monkeypox","author":"Moore","year":"2022"},{"key":"10.1016\/j.jobb.2022.12.004_b0035","first-page":"853","article-title":"The First Imported Case of Monkeypox in the Mainland of China - Chongqing Municipality, China, September 16, 2022","volume":"4","author":"Zhao","year":"2022","journal-title":"China CDC Wkly"},{"key":"10.1016\/j.jobb.2022.12.004_b0040","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23147866","article-title":"Monkeypox: A New Threat?","volume":"23","author":"Kmiec","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jobb.2022.12.004_b0045","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nrmicro1099","article-title":"Poxvirus tropism","volume":"3","author":"McFadden","year":"2005","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jobb.2022.12.004_b0050","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0140-6736(22)01436-2","article-title":"Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study","volume":"400","author":"Tarin-Vicente","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jobb.2022.12.004_b0055","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nri1489","article-title":"Retroviral restriction by APOBEC proteins","volume":"4","author":"Harris","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jobb.2022.12.004_b0060","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-022-01907-y","article-title":"Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus","volume":"28","author":"Isidro","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jobb.2022.12.004_b0065","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41392-022-01181-x","article-title":"The monkeypox outbreak in 2022: adaptive evolution associated with APOBEC3 may account for","volume":"7","author":"Chen","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jobb.2022.12.004_b0070","doi-asserted-by":"crossref","unstructured":"Karim F, Moosa MYS, Gosnell BI, et al. 2021. Persistent SARS-CoV-2 infection and intra-host evolution in association with advanced HIV infection doi:10.1101\/2021.06.03.21258228. medRxiv.","DOI":"10.1101\/2021.06.03.21258228"},{"key":"10.1016\/j.jobb.2022.12.004_b0075","doi-asserted-by":"crossref","first-page":"e0188453","DOI":"10.1371\/journal.pone.0188453","article-title":"Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments","volume":"13","author":"Noyce","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jobb.2022.12.004_b0080","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nature02331","article-title":"Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox","volume":"428","author":"Earl","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.jobb.2022.12.004_b0085","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1128\/JVI.02642-05","article-title":"LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox","volume":"80","author":"Saijo","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.jobb.2022.12.004_b0090","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.vaccine.2007.10.063","article-title":"Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge","volume":"26","author":"Marriott","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.jobb.2022.12.004_b0095","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/nm1261","article-title":"Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus","volume":"11","author":"Edghill-Smith","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.jobb.2022.12.004_b0100","article-title":"Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals","author":"Zaeck","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jobb.2022.12.004_b0105","doi-asserted-by":"crossref","unstructured":"Turner M, Mandia J, Keltner C, Haynes R, Faestel P, Mease L. 2022. Monkeypox in Patient Immunized with ACAM2000 Smallpox Vaccine During 2022 Outbreak. Emerg Infect Dis 28.","DOI":"10.3201\/eid2811.221215"},{"key":"10.1016\/j.jobb.2022.12.004_b0110","article-title":"Immunization of mice with vaccinia virus Tiantan strain yields antibodies cross-reactive with protective antigens of monkeypox virus","author":"Yang","year":"2022","journal-title":"Virol Sin"},{"key":"10.1016\/j.jobb.2022.12.004_b0115","doi-asserted-by":"crossref","unstructured":"Khlusevich Y, Matveev A, Emelyanova L, Goncharova E, Golosova N, Pereverzev I, Tikunova N. 2022. New p35 (H3L) Epitope Involved in Vaccinia Virus Neutralization and Its Deimmunization. Viruses 14.","DOI":"10.3390\/v14061224"},{"key":"10.1016\/j.jobb.2022.12.004_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2009.06.006","article-title":"Vaccinia virus vaccines: past, present and future","volume":"84","author":"Jacobs","year":"2009","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jobb.2022.12.004_b0125","doi-asserted-by":"crossref","unstructured":"Halsell JS, Riddle JR, Atwood JE, et al., 2003. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. JAMA 289:3283-9.","DOI":"10.1001\/jama.289.24.3283"},{"key":"10.1016\/j.jobb.2022.12.004_b0130","unstructured":"Centers for Disease C, Prevention. 2003. Update: cardiac and other adverse events following civilian smallpox vaccination--United States, 2003. MMWR Morb Mortal Wkly Rep 52:639-42."},{"key":"10.1016\/j.jobb.2022.12.004_b0135","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1371\/journal.pmed.0030272","article-title":"Frequency of adverse events after vaccination with different vaccinia strains","volume":"3","author":"Kretzschmar","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.jobb.2022.12.004_b0140","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.vaccine.2008.11.079","article-title":"Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults","volume":"27","author":"Frey","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.jobb.2022.12.004_b0145","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/DDDT.S3687","article-title":"ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile","volume":"4","author":"Nalca","year":"2010","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jobb.2022.12.004_b0150","doi-asserted-by":"crossref","first-page":"7805","DOI":"10.1128\/JVI.03481-12","article-title":"Assessment of the protective effect of Imvamune and Acam 2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques","volume":"87","author":"Hatch","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.jobb.2022.12.004_b0155","doi-asserted-by":"crossref","first-page":"11873","DOI":"10.1128\/JVI.79.18.11873-11891.2005","article-title":"An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection","volume":"79","author":"Morikawa","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.jobb.2022.12.004_b0160","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1016\/j.vaccine.2006.03.087","article-title":"LC16m8: an attenuated smallpox vaccine","volume":"24","author":"Kenner","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.jobb.2022.12.004_b0165","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/infdis\/jiq162","article-title":"Smallpox vaccine safety is dependent on T cells and not B cells","volume":"203","author":"Gordon","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jobb.2022.12.004_b0170","doi-asserted-by":"crossref","first-page":"408","DOI":"10.7883\/yoken.JJID.2016.417","article-title":"A Single Vaccination of Nonhuman Primates with Highly Attenuated Smallpox Vaccine, LC16m8, Provides Long-term Protection against Monkeypox","volume":"70","author":"Iizuka","year":"2017","journal-title":"Jpn J Infect Dis"},{"key":"10.1016\/j.jobb.2022.12.004_b0175","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1128\/CVI.00782-14","article-title":"Use of the LC16m8 Smallpox Vaccine in Immunocompromised Individuals Is Still Too Risky","volume":"22","author":"Danon","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.jobb.2022.12.004_b0180","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1128\/CVI.00055-15","article-title":"Reply to \u201cUse of the LC16m8 Smallpox Vaccine in Immunocompromised Individuals Is Still Too Risky\u201d","volume":"22","author":"Yokote","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.jobb.2022.12.004_b0185","first-page":"889","article-title":"Smallpox vaccine: contraindications, administration, and adverse reactions","volume":"68","author":"Maurer","year":"2003","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.jobb.2022.12.004_b0190","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/bs.aivir.2016.07.001","article-title":"Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development","volume":"97","author":"Volz","year":"2017","journal-title":"Adv Virus Res"},{"issue":"Pt 2","key":"10.1016\/j.jobb.2022.12.004_b0195","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1099\/0022-1317-79-2-347","article-title":"Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells","volume":"79","author":"Drexler","year":"1998","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jobb.2022.12.004_b0200","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1073\/pnas.1921098117","article-title":"Repair of a previously uncharacterized second host-range gene contributes to full replication of modified vaccinia virus Ankara (MVA) in human cells","volume":"117","author":"Peng","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jobb.2022.12.004_b0205","doi-asserted-by":"crossref","first-page":"e1007710","DOI":"10.1371\/journal.ppat.1007710","article-title":"SPI-1 is a missing host-range factor required for replication of the attenuated modified vaccinia Ankara (MVA) vaccine vector in human cells","volume":"15","author":"Liu","year":"2019","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jobb.2022.12.004_b0210","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0042-6822(92)90752-B","article-title":"NYVAC: a highly attenuated strain of vaccinia virus","volume":"188","author":"Tartaglia","year":"1992","journal-title":"Virology"},{"key":"10.1016\/j.jobb.2022.12.004_b0215","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1099\/vir.0.2008\/004440-0","article-title":"Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax","volume":"89","author":"Midgley","year":"2008","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jobb.2022.12.004_b0220","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1128\/JVI.01706-07","article-title":"Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax","volume":"82","author":"Davies","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.jobb.2022.12.004_b0225","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.1128\/JVI.02108-05","article-title":"Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene","volume":"80","author":"Najera","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.jobb.2022.12.004_b0230","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3389\/fcimb.2020.00116","article-title":"Non-replicating Vaccinia Virus TianTan Strain (NTV) Translation Arrest of Viral Late Protein Synthesis Associated With Anti-viral Host Factor SAMD9","volume":"10","author":"Zhao","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.jobb.2022.12.004_b0235","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1600-065X.2010.00975.x","article-title":"Smallpox vaccines: targets of protective immunity","volume":"239","author":"Moss","year":"2011","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jobb.2022.12.004_b0240","doi-asserted-by":"crossref","first-page":"12355","DOI":"10.1128\/JVI.01593-09","article-title":"Heavily isotype-dependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5","volume":"83","author":"Benhnia","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.jobb.2022.12.004_b0245","doi-asserted-by":"crossref","first-page":"e1005148","DOI":"10.1371\/journal.ppat.1005148","article-title":"Structural and Functional Characterization of Anti-A33 Antibodies Reveal a Potent Cross-Species Orthopoxviruses Neutralizer","volume":"11","author":"Matho","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jobb.2022.12.004_b0250","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1128\/JVI.02878-15","article-title":"Linear Epitopes in Vaccinia Virus A27 Are Targets of Protective Antibodies Induced by Vaccination against Smallpox","volume":"90","author":"Kaever","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.jobb.2022.12.004_b0255","doi-asserted-by":"crossref","first-page":"11339","DOI":"10.1128\/JVI.01491-14","article-title":"Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein","volume":"88","author":"Kaever","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.jobb.2022.12.004_b0260","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.virol.2006.07.017","article-title":"Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen","volume":"355","author":"Sakhatskyy","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.jobb.2022.12.004_b0265","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3851\/IMP1573","article-title":"Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model","volume":"15","author":"McCausland","year":"2010","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jobb.2022.12.004_b0270","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1006\/viro.2001.1131","article-title":"The A17L gene product of vaccinia virus is exposed on the surface of IMV","volume":"290","author":"Wallengren","year":"2001","journal-title":"Virology"},{"issue":"684\u2013694","key":"10.1016\/j.jobb.2022.12.004_b0275","first-page":"e9","article-title":"Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections","volume":"167","author":"Gilchuk","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jobb.2022.12.004_b0280","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1006\/viro.1998.9516","article-title":"Neutralizing and protective antibodies directed against vaccinia virus envelope antigens","volume":"254","author":"Galmiche","year":"1999","journal-title":"Virology"},{"key":"10.1016\/j.jobb.2022.12.004_b0285","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.virol.2005.09.056","article-title":"Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host","volume":"345","author":"Fang","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.jobb.2022.12.004_b0290","doi-asserted-by":"crossref","first-page":"10230","DOI":"10.1128\/JVI.78.19.10230-10237.2004","article-title":"Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions","volume":"78","author":"Fogg","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.jobb.2022.12.004_b0295","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.vaccine.2006.10.009","article-title":"A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost","volume":"25","author":"Xiao","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.jobb.2022.12.004_b0300","doi-asserted-by":"crossref","first-page":"6627","DOI":"10.1016\/j.vaccine.2010.07.030","article-title":"A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge","volume":"28","author":"Buchman","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.jobb.2022.12.004_b0305","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1128\/JVI.01854-07","article-title":"Vaccination of BALB\/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge","volume":"82","author":"Berhanu","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.jobb.2022.12.004_b0310","series-title":"Janeway's Immunobiology","author":"Murphy","year":"2017"},{"key":"10.1016\/j.jobb.2022.12.004_b0315","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1128\/JVI.78.9.4433-4443.2004","article-title":"Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox","volume":"78","author":"Hooper","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.jobb.2022.12.004_b0320","doi-asserted-by":"crossref","first-page":"e42353","DOI":"10.1371\/journal.pone.0042353","article-title":"Side-by-side comparison of gene-based smallpox vaccine with MVA in nonhuman primates","volume":"7","author":"Golden","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jobb.2022.12.004_b0325","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/infdis\/jiq017","article-title":"Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge","volume":"203","author":"Hirao","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jobb.2022.12.004_b0330","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.coi.2009.05.016","article-title":"Heterologous prime-boost vaccination","volume":"21","author":"Lu","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jobb.2022.12.004_b0335","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.4049\/jimmunol.177.4.2552","article-title":"Subunit recombinant vaccine protects against monkeypox","volume":"177","author":"Heraud","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.jobb.2022.12.004_b0340","doi-asserted-by":"crossref","unstructured":"Sang Y, Zhang Z, Liu F, et al. 2022. Monkeypox virus quadrivalent mRNA vaccine induces antibody responses and cellular immunity and protects mice against Vaccinia virus. bioRxiv doi:10.1101\/2022.11.22.517500:2022.11.22.517500.","DOI":"10.1101\/2022.11.22.517500"},{"key":"10.1016\/j.jobb.2022.12.004_b0345","doi-asserted-by":"crossref","unstructured":"Hou F, Zhang Y, Liu X, et al. 2022. Novel mRNA vaccines encoding Monkeypox virus M1R and A35R protect mice from a lethal virus challenge. bioRxiv doi:10.1101\/2022.11.19.517190:2022.11.19.517190.","DOI":"10.1101\/2022.11.19.517190"},{"key":"10.1016\/j.jobb.2022.12.004_b0350","doi-asserted-by":"crossref","first-page":"13139","DOI":"10.1128\/JVI.79.20.13139-13149.2005","article-title":"An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge","volume":"79","author":"Yang","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.jobb.2022.12.004_b0355","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/jac\/dku545","article-title":"ST-246 is a key antiviral to inhibit the viral F13L phospholipase, one of the essential proteins for orthopoxvirus wrapping","volume":"70","author":"Duraffour","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jobb.2022.12.004_b0360","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02154-17","article-title":"Vaccinia Virus Phospholipase Protein F13 Promotes Rapid Entry of Extracellular Virions into Cells","volume":"92","author":"Bryk","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.jobb.2022.12.004_b0365","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1128\/JVI.73.2.1108-1117.1999","article-title":"Envelope formation is blocked by mutation of a sequence related to the HKD phospholipid metabolism motif in the vaccinia virus F13L protein","volume":"73","author":"Roper","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.jobb.2022.12.004_b0370","doi-asserted-by":"crossref","DOI":"10.1038\/s41564-022-01269-8","article-title":"Tecovirimat is effective against human monkeypox virus in vitro at nanomolar concentrations","author":"Frenois-Veyrat","year":"2022","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.jobb.2022.12.004_b0375","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1128\/AAC.00021-09","article-title":"Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246","volume":"53","author":"Huggins","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jobb.2022.12.004_b0380","unstructured":"Anonymous. 2012. Brincidofovir, LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, Bethesda (MD)."},{"key":"10.1016\/j.jobb.2022.12.004_b0385","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.3390\/v2122740","article-title":"Development of CMX001 for the Treatment of Poxvirus Infections","volume":"2","author":"Lanier","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.jobb.2022.12.004_b0390","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S1473-3099(22)00228-6","article-title":"Clinical features and management of human monkeypox: a retrospective observational study in the UK","volume":"22","author":"Adler","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jobb.2022.12.004_b0395","first-page":"2803","volume":"2","author":"Andrei","year":"2010","journal-title":"Cidofovir Activity against Poxvirus Infections. Viruses"},{"key":"10.1016\/j.jobb.2022.12.004_b0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-3542(02)00008-6","article-title":"Cidofovir in the treatment of poxvirus infections","volume":"55","author":"De Clercq","year":"2002","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jobb.2022.12.004_b0405","article-title":"Human monkeypox outbreak: epidemiological data and therapeutic potential of topical cidofovir in a prospective cohort study","author":"Sobral-Costas","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jobb.2022.12.004_b0410","first-page":"13","article-title":"Susceptibility of some rodent species to monkeypox virus, and course of the infection","volume":"53","author":"Marennikova","year":"1976","journal-title":"Bull World Health Organ"}],"container-title":["Journal of Biosafety and Biosecurity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588933822000292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588933822000292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:52:30Z","timestamp":1762876350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588933822000292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S2588933822000292"],"URL":"https:\/\/doi.org\/10.1016\/j.jobb.2022.12.004","relation":{},"ISSN":["2588-9338"],"issn-type":[{"value":"2588-9338","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential threat of human pathogenic orthopoxviruses to public health and control strategies","name":"articletitle","label":"Article Title"},{"value":"Journal of Biosafety and Biosecurity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jobb.2022.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.","name":"copyright","label":"Copyright"}]}}